Zogenix, Inc. (ZGNX)
-NasdaqGM 1.53 
0.01(0.72%) 12:45PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.52 |
|---|
| Open: | 1.53 |
|---|
| Bid: | 1.53 x 800 |
|---|
| Ask: | 1.54 x 4700 |
|---|
| 1y Target Est: | 3.67 |
|---|
| Beta: | 2.68 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.50 - 1.55 |
|---|
| 52wk Range: | 1.11 - 3.30 |
|---|
| Volume: | 229,184 |
|---|
| Avg Vol (3m): | 1,208,460 |
|---|
| Market Cap: | 154.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.65 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Zogenix and Battelle to present positive, new data demonstrating value of needle-free injection for biologics; dosepro studies to be presented at 2013 AAPS National Biotechnology ConferenceBriefing.com(Mon, May 20)
- Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for BiologicsGlobeNewswire(Mon, May 20)
- ZOGENIX, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Did These Healthcare Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sun, May 12)
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarinat TheStreet(Fri, May 10)
- Zogenix's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Zogenix Earnings: Here’s Why Investors are Selling Shares Nowat Wall St. Cheat Sheet(Thu, May 9)
- Zogenix, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Thu, May 9)
- Zogenix Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 9)
- ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- Q1 2013 Zogenix, Inc. Earnings Release - After Market CloseCCBN(Thu, May 9)
- Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 3)
- Zogenix Poised For 40% Haircut As Zohydro Decision Approachesat Seeking Alpha(Thu, May 2)
- ZOGENIX, INC. Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 2)
- Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical TrialGlobeNewswire(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4.65 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.59 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.11 |
|---|
Business Summary
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
View More